We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Enhanced Silencing Longevity of siRNA

By Biotechdaily staff writers
Posted on 15 Jan 2004
A proprietary form of small interfering RNA (siRNA) called siStable siRNA has been modified to significantly enhance stability, potency, and silencing longevity while decreasing cellular toxicity.

In comparative cell culture studies, siStable siRNA maintains full silencing potency after seven days. In human serum, where nucleases break down unmodified siRNA, siStable siRNA half-life is increased more than 500-fold from minutes to over 85 hours. The siStable siRNA modifications also alter siRNA processing within the cell, increasing gene silencing potency and specificity. These data were presented at the annual meeting of the American Society for Cell Biology in San Francisco (CA, USA).

To develop siStable siRNA, scientists at Dharmacon, Inc. (Lafayette, CO, USA) chemically modified the siRNA strands in a novel and proprietary manner. The new product builds on previous modifications contained in Dharmacon's On-Target siRNA that inactivate the siRNA sense strand, completely eliminating its potential role in causing off-target silencing. Microarray gene expression analysis studies to date have shown no cellular toxicity from use of siStable siRNA.

"We are committed to working with life science researchers to make the potential advantages of RNAi widely available for an increasing range of biomedical applications,” said Stephen A. Scaringe, Ph.D., co-chairman and chief scientific officer at Dharmacon.




Related Links:
Dharmacon

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
15 Jan 2004  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
15 Jan 2004  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
15 Jan 2004  |   BioResearch